MPM BioImpact — 2026 Investments

3 investments dated 2026 · listed companies and verified rows first · show all

Epi Biologicsepibiologics.com inSeries B · Jan 2026 · $110M

Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.

BiotechMedical DevicesSan Mateo, US

Ann Lee-Karlon(Executive Officer, Director)inMitchell Mutz(Executive Officer, Director)James Wells(Director)

BoardSamuel Bjork(Director)inAlexandra Cantley(Director)inSeiji Miyahara(Director)in

Co-investorsAvego BioScience Capital GV (Google Ventures)Mission Biocapital Novartis Venture Fund Roche Venture Fund Samsara BioCapital +4 more

K2 Spacek2space.io in 𝕏Aug 2026 · $50M

The page is an online gambling/betting operator ("OK9") targeting Vietnamese players, offering sports betting, online casino, slots, fish-shooting games, lottery, and card games.

Deep TechHardwareSpace TechWest Hollywood, US

Neeldev Kunjur(Executive Officer, Director)Karandev Kunjur(Executive Officer, Director)Karan Kunjur(Founder)inNeel Kunjur(Founder)in

Co-investorsAlpine Space Ventures Also Capital Asymmetric Capital Partners CapitalG Earthrise Ventures First Round Capital +22 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

K2 Therapeutics

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.